UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported):  July 31, 2012

 

AmerisourceBergen Corporation

(Exact name of Registrant as specified in its charter)

 

Delaware

 

1-16671

 

23-3079390

(State or Other

Jurisdiction of

Incorporation or

Organization)

 

Commission File Number

 

(I.R.S. Employer

Identification

Number)

 

 

1300 Morris Drive

Chesterbrook, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (610) 727-7000

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01.                                        Other Events.

 

On July 31, 2012, AmerisourceBergen Corporation (the “Registrant”) issued a news release announcing that the Registrant had signed a three year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis.  The agreement is effective October 1, 2012.

 

The contract is expected to contribute approximately 23 percent of the Registrant’s revenues, and about 3 percent of its earnings per share. The contract award has no impact on the Registrant’s expectations for fiscal 2012 or on its preliminary expectations for fiscal 2013, which the Registrant previously disclosed in a news release issued on July 26, 2012.

 

A copy of the news release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d)                                 Exhibits.

 

99.1                        News Release, dated July 31, 2012, of AmerisourceBergen Corporation, regarding Registrant’s three year pharmaceutical supply agreement with Express Scripts.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AMERISOURCEBERGEN CORPORATION

 

 

Date: August 1, 2012

By:

/s/ Tim G. Guttman

 

Name:

Tim G. Guttman

 

Title:

Senior Vice President and Chief Financial Officer

 

3